GVHD
Of the 85 patients evaluated, 24 patients (28.2%) experienced aGVHD,
while seven patients (8.2%) developed moderate to severe (grades
II–IV) aGVHD. Among the evaluated patients, 13 (15.3%) developed
cGVHD. The aGVHD incidence differed statistically across the four
groups, while that of cGVHD did not (Fig. 2). The cumulative incidences
of grade II–IV aGVHD were 13.33% and 27.28% in the ABO-compatible and
-major incompatibility groups, respectively, while the other groups had
0% incidence (P = 0.258).